InMed Pharmaceuticals (INM) Net Cash Flow (2019 - 2026)

InMed Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 216.11% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was $811547.0, a 127.79% increase from a year earlier, with the FY2025 full-year figure at $4.5 million, up 292.42% from the prior year.
• Net Cash Flow rose to -$1.5 million in Q1 2026 per INM's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $6.4 million in Q2 2025 and bottomed at -$5.4 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$1.5 million (2026), against an average of -$584314.2.
• Across the five-year window, Net Cash Flow tumbled 849.58% in 2022 and surged 721.59% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $2.6 million in 2022, then plunged by 171.02% to -$1.8 million in 2023, then fell by 17.07% to -$2.2 million in 2024, then fell by 9.83% to -$2.4 million in 2025, then surged by 38.41% to -$1.5 million in 2026.
• Per Business Quant, the three latest INM Net Cash Flow figures stand at -$1.5 million (Q1 2026), -$2.4 million (Q4 2025), and -$1.7 million (Q3 2025).